盐酸丙酰左卡尼汀(Levocarnitine propionate hydrochloride) - 药物靶点：PDHK_在研适应症：外周血管疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

L-Carnitine propionate、Levocarnitine propionate hydrochloride (USAN)、Levocarnitine proprionate

+ [10]

靶点

PDHK

作用方式

刺激剂

作用机制

PDHK刺激剂(丙酮酸脱氢激酶刺激剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构-

非在研机构

Alfasigma SpA

李氏大药厂控股有限公司

Sigma-Tau Industrie Farmaceutiche Riunite SpA

+ [1]

权益机构-

最高研发阶段批准上市

首次获批日期

意大利 (1998-01-01),

心脏衰竭外周血管疾病

最高研发阶段(中国)终止

特殊审评-

登录后查看时间轴

结构/序列

分子式C10H20ClNO4

InChIKeyKTFMPDDJYRFWQE-DDWIOCJRSA-N

CAS号119793-66-7

关联

58

项与盐酸丙酰左卡尼汀相关的临床试验

IRCT20170609034406N10

/ Suspended临床2/3期IIT

The potential effect of parenteral L-carnitine on hospitalized patients with moderate to severe COVID-19

开始日期2023-02-20

申办/合作机构

Tabriz University of Medical Sciences

IRCT20221128056646N1

/ Recruiting临床4期IIT

Assessment of effect of L-Carnitine supplement on subclinical LV systolic dysfunction detected by speckletracking echocardiography in patients with ESRD under hemodiylisis

开始日期2022-12-21

申办/合作机构

Shiraz University of Medical Sciences

IRCT20210412050944N2

/ Recruiting临床2期IIT

Assessment of the effectiveness of L-carnitine and curcumin in the treatment of non-alcoholic fatty liver in patients aged 5 to 15 years old

开始日期2022-09-23

申办/合作机构

Qazvin University of Medical Sciences

100 项与盐酸丙酰左卡尼汀相关的临床结果

登录后查看更多信息

100 项与盐酸丙酰左卡尼汀相关的转化医学

登录后查看更多信息

100 项与盐酸丙酰左卡尼汀相关的专利（医药）

登录后查看更多信息

489

项与盐酸丙酰左卡尼汀相关的文献（医药）

2025-04-01·Diabetes, Obesity and Metabolism

Efficacy of myo‐inositol and zinc on insulin resistance in a paediatric population with obesity

Article

作者: Antoniotti, Valentina ; Rabbone, Ivana ; Medina, Federico ; Prodam, Flavia ; Sista, Maria T. ; Monzani, Alice ; Bellone, Simonetta ; Agostini, Alida ; Baima, Jessica ; Partenope, Cristina ; Scotti, Lorenza ; Mancioppi, Valentina ; Solito, Arianna ; Dimarakis, Sotirios

AbstractAimTo assess the efficacy of the combined administration of myo‐inositol and zinc, a mineral involved in the insulin pathway, in paediatric obesity with insulin resistance on HOMA‐IR, glucose‐insulin metabolism, and lipid profile.Materials and MethodsDouble‐blind, randomized, placebo‐controlled study conducted in North Italy. Fifty‐six patients (10–18 years, Tanner stage ≥3) with obesity and insulin resistance were randomized to myo‐inositol (2000 mg), zinc gluconate (5 mg), and galactooligosaccharides (GOS) from plant‐based origin (1000 mg) (TRT) or placebo (PLC) containing only GOS from plant‐based origin (1000 mg). All patients received an isocaloric diet following the Mediterranean diet style. Data were collected at baseline (V0) and after 3 months (V1). The primary outcome was the insulin resistance index (HOMA‐IR).ResultsFifty out of 56 recruited subjects completed the study. TRT improved HDL cholesterol level compared to PLC (p = 0.05) but not insulin resistance. A stratified post hoc analysis was performed by sex, BMI, and subgroups of adherence to the Mediterranean diet. Subjects were divided for obesity grade, fasting insulin (p = 0.0137) and HOMA‐IR (p = 0.0273) were lower in TRT than in PLC patients, with a greater effect on severe obesity. No adverse events were detected.ConclusionThree months of supplementation with myo‐inositol and zinc were beneficial on lipid profile and in managing obesity complications at least in subjects with severe phenotype. Thus, myo‐inositol and zinc could be used as non‐pharmacological agents. This work suggests a long‐term study with a larger sample size to enrich the findings.

2025-03-01·BMJ Open

NapBiome trial: Targeting gut microbiota to improve sleep rhythm and developmental and behavioural outcomes in early childhood in a birth cohort in Switzerland – a study protocol

Article

作者: Giannoukos, Stamatios ; Bokulich, Nicholas A ; Kurth, Salome ; Stocker, Martin ; Zimmermann, Petra

IntroductionThe gut–brain axis plays a crucial role in the regulation and development of psychological and physical processes. The first year of life is a critical period for the development of the gut microbiome, which parallels important milestones in establishing sleep rhythm and brain development. Growing evidence suggests that the gut microbiome influences sleep, cognition and early neurodevelopment. For term-born and preterm-born infants, difficulties in sleep regulation may have consequences on health. Identifying effective interventions on the gut–brain axis in early life is likely to have long-term implications for the health and development of at-risk infants.Methods and analysesIn this multicentre, four-group, double-blinded, placebo (PLC)-controlled randomised trial with a factorial design, 120 preterm-born and 260 term-born infants will be included. The study will investigate whether the administration of daily synbiotics or PLC for a duration of 3 months improves sleep patterns and neurodevelopmental outcomes up to 2 years of age. The trial will also: (1) determine the association between gut microbiota, sleep patterns and health outcomes in children up to 2 years of age; and (2) leverage the interactions between gut microbiota, brain and sleep to develop new intervention strategies for at-risk infants.Ethics and disseminationThe NapBiome trial has received ethical approval by the Committee of Northwestern and Central Switzerland and Canton Vaud, Switzerland (#2024–01681). Outcomes will be disseminated through publication and will be presented at scientific conferences. Metagenomic data will be shared through the European Nucleotide Archive.Trial registration numberThe US National Institutes of HealthNCT06396689.

2025-01-01·Journal of Veterinary Dentistry

Serum Cortisol and Blood Glucose Concentrations in Anesthetized Dogs Administered Levobupivacaine and Low-Dose Dexmedetomidine for Regional Anesthesia of the Oral Cavity

Article

作者: Seliškar, Alenka ; Pavlica, Matic ; Baš, Anže ; Kržan, Mojca ; Nemec, Marija ; Nemec, Ana ; Kosjek, Tina

The effects on the stress response, postanesthetic sedation, and altered behavior were evaluated following regional anesthesia and dental treatment in 40 dogs. Serum cortisol and blood glucose concentrations were measured following the administration of levobupivacaine (LBUP) 0.5% and dexmedetomidine (DEX) (0.5 µg/kg) or a placebo. The dogs were randomly assigned to 4 groups of 10 dogs each. All dogs received a regional nerve block using LBUP 0.5%. Group 1 (LBUP + DEX IV) also received DEX intravenously (IV); group 2 (LBUP + PLC IV) also received a placebo IV; group 3 (LBUP + DEX IO) also received DEX in one infraorbital (IO) block; and group 4 (LBUP + DEX IA) also received DEX in one inferior alveolar (IA) block. Serum cortisol and blood glucose concentrations were determined before the administration of oral blocks and at the end of the procedure. Sedation and behavior scores were assessed before premedication and hourly for 6 h after the end of anesthesia. Cortisol concentration did not change in any group at either evaluation time. The glucose concentration was higher ( P < .05) only in the LBUP + DEX IA group at the end of the procedure. The sedation score was higher until the end of the observation period only in the LBUP + DEX IV and LBUP + PLC IV groups. No change in behavior score was observed in any of the groups. The reduction of perioperative stress response in all groups was due to the use of LBUP and not DEX.

100 项与盐酸丙酰左卡尼汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04713	-	A16AA01	DB15980

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
外周血管疾病	意大利	-	1998-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
外周动脉疾病	临床3期	中国	李氏大药厂控股有限公司	2008-05-01
间歇性跛行	临床3期	美国	Alfasigma SpA	2006-04-01
外周血管疾病	临床3期	美国	Alfasigma SpA	2006-04-01
外周动脉闭塞性疾病	临床3期	美国	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-
溃疡性结肠炎	临床前	德国	Alfasigma SpA	2012-04-01
溃疡性结肠炎	临床前	罗马尼亚	Alfasigma SpA	2012-04-01
溃疡性结肠炎	临床前	法国	Alfasigma SpA	2012-04-01
溃疡性结肠炎	临床前	荷兰	Alfasigma SpA	2012-04-01
外周动脉闭塞性疾病	临床前	美国	Sigma-Tau Industrie Farmaceutiche Riunite SpA	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2022	N/A	头颈部肿瘤	150	L-carnitine 500mg	(齋鏇簾網鹽簾蓋鏇顧窪) = 糧願餘遞鹽壓觸餘積襯齋構願構齋齋築襯衊選 (襯遞簾遞艱顧範憲顧獵 )	-	2022-09-10
				L-carnitine (Control)	(齋鏇簾網鹽簾蓋鏇顧窪) = 築鬱夢顧積衊繭築觸範齋構願構齋齋築襯衊選 (襯遞簾遞艱顧範憲顧獵 )
NCT03297944 (CTgov)	临床4期	精神运动性障碍	15	Placebo (PLC/PLC)+ZOL+PLC+Alprazolam+Zolpidem+ALC	築積獵鑰蓋繭襯築鹽衊(製齋範範窪願壓鏇衊鹹) = 襯顧鏇繭觸積範繭願壓艱蓋簾襯襯窪鑰積構遞 (觸醖製膚淵積獵鹹選獵, 築鏇襯餘窪壓糧願鹽齋 ~ 鑰鹹積膚淵鏇製夢遞艱) 更多	-	2020-01-29
NCT01107730 (CTgov)	临床3期	心房颤动	33	L-carnitine (L-Carnitine)	簾簾積鬱鑰壓醖製廠鏇(構醖積鏇繭獵壓衊鏇選) = 蓋廠餘積憲鹹簾餘膚鹽艱願壓憲鏇淵餘膚齋餘 (廠襯醖鹽鏇選遞壓網醖, 鏇蓋製襯齋築鹽醖觸築 ~ 窪壓壓願獵選夢簾淵衊) 更多	-	2015-05-13
				Vitamin C (Vitamin C)	簾簾積鬱鑰壓醖製廠鏇(構醖積鏇繭獵壓衊鏇選) = 齋觸鹽齋壓夢艱壓艱遞艱願壓憲鏇淵餘膚齋餘 (廠襯醖鹽鏇選遞壓網醖, 網鹹廠窪齋築選廠衊襯 ~ 鹽網遞鏇壓網餘觸襯積) 更多
NCT00399919 (Pubmed \| J Cardiopulm Rehabil Prev)	临床3期	外周动脉疾病	69	Propionyl-L-carnitine	廠積夢觸鹽築憲餘觸遞(製憲顧積繭艱範選淵獵) = 鑰襯鬱鹽蓋艱醖蓋鑰繭選積鏇網獵願顧糧遞淵 (構膚鏇築構膚醖鏇蓋憲 )	-	2011-03-01
				Placebo	廠積夢觸鹽築憲餘觸遞(製憲顧積繭艱範選淵獵) = 憲鹽襯醖構願鹹積餘繭選積鏇網獵願顧糧遞淵 (構膚鏇築構膚醖鏇蓋憲 )